Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD

In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval.

After two decades of rigorous development, this innovative treatment was administered to its inaugural commercial patient, a high-risk leukemia sufferer.

Notably, Orca-T significantly minimizes the chances of graft-versus-host disease post-stem cell transplants, offering reduced chemotherapy requirements and lower side effects.

Future studies are anticipated to investigate its relevance for broader patient demographics.